Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
about
Acute promyelocytic leukemia: where did we start, where are we now, and the futureAcute Promyelocytic Leukemia (APL): Comparison Between Children and AdultsInternal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeCuring all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemiaSingle-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Acute myeloid leukemia, version 2.2013.SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centreHigh-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARAReal-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapyEpidemiology and treatment of acute promyelocytic leukemia in latin americaAcute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraThe differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literatureNewly diagnosed acute promyelocytic leukemiaResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaBudgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.Retinoic acid-induced differentiation increases the rate of oxygen consumption and enhances the spare respiratory capacity of mitochondria in SH-SY5Y cells.All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.Emerging new approaches for the treatment of acute promyelocytic leukemia.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsThe results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countriesCurrent routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea.Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidCost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the LiteratureHow I treat children and adolescents with acute promyelocytic leukaemia.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.Integrating microRNA and mRNA expression profiles of acute promyelocytic leukemia cells to explore the occurrence mechanisms of differentiation syndrome.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia
P2860
Q26830385-9631F3D7-CC4E-4208-9DF9-D7E208CC45A2Q27009433-ED40BFBA-6B4C-401F-B4EA-5D6E6E6EC1B5Q27853031-59690F0C-7725-487F-9251-3103EEB17830Q33613426-5963DF13-F553-40A1-98E6-A517E1D37106Q33631350-6E0743DF-0C7C-4379-9B5A-7CA5761C197FQ33746130-4CE4CE64-D77D-4744-9007-1D8693BFCA09Q33800102-02C875E6-9A5B-4A1B-B304-5A491495295DQ34046794-5F14FA85-ED7D-4B9A-9234-6A0A17653AC7Q34165330-B9630105-0A87-4D97-838A-60BBBB55EB00Q34226368-54210996-4D3E-4ED1-8615-53EC9C2FAF68Q34227027-B6589922-7CF0-435D-91CA-6626F2A03B25Q34750640-F3F66C2E-8DBD-4C1F-8D54-7E290C59E915Q34953881-F42D83A9-4098-405D-9A40-26CDDE3D79FBQ35062053-FDBE8CA6-263C-4DBC-AC51-767E369C83A6Q35537150-C08EAB0F-7050-42C0-9618-6493C0C5F9FCQ35560268-54AC2EB0-ADBC-4ED9-9648-F0440333F8B6Q35640734-6BA3242C-B8D5-47D4-B971-B705FE74A277Q35640755-EA14C1CF-5D0A-44D7-9A62-0368C9AF1D9BQ35640773-431A45A2-995C-45EF-A6FA-F0AFF186D3D5Q35717816-A9BCB339-C36B-4A30-9451-942E05158CB9Q35743980-9A6CA35E-8698-4848-82FB-EEF2CC27EF05Q35975751-671DE020-39E1-43C6-82C2-6D4272972968Q36070904-EFB3DED3-31EC-4B6D-A932-A3CD7DE260A9Q36303245-A469B773-C5A2-41BC-8164-F5868AAC54FFQ36508333-50EE0BA6-2903-48A9-AEE5-3AFA7DA7E38DQ36612619-8E7D7512-6EBE-43EE-BD41-71F1765C6124Q36740744-DCEA268E-980D-4B08-ADA9-0E2664B7CF0CQ36753253-13D3F2B0-9370-4949-AD0E-92AB88EE54EFQ36761829-5D3CAA7E-E8DE-4F98-A40A-32C602641A51Q36805563-D63B475B-2DA8-4ED3-A23E-23C6D671BCACQ37216174-AF597BBD-E8AB-4EDF-858F-88F34E2D8921Q37267500-3ABB308E-481A-414C-A441-910B132B08AEQ37418961-90EEF141-D441-41F8-9089-4252D93FBA93Q37451376-16C42745-5E85-4383-A818-3E1BB037847AQ37565126-3B51D262-5DF6-474E-9114-D52AAF137F36Q37628630-246F5869-26BB-4AE1-9DE4-A81510DBDCDAQ37683361-F5827303-4B19-4254-8D81-66B5D92F4200Q37687421-1D7D8DC9-7424-4FF2-81CC-E8EC0E432A06Q37712353-AF218F97-08F4-468E-B954-846DF103106CQ37899041-69A124B4-4413-4142-AE00-321DAF6B1049
P2860
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@ast
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@en
type
label
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@ast
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@en
prefLabel
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@ast
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@en
P2093
P50
P1433
P1476
Risk-adapted treatment of acut ...... ovements in treatment outcome.
@en
P2093
Alexandra Holowiecka
Chelo Rayón
Concha Rivas
Elena de Lisa
Félix Manso
Gert Ossenkoppele
Gustavo Milone
Isabel Krsnik
Joaquín Díaz-Mediavilla
José D González
P304
P356
10.1182/BLOOD-2010-01-266007
P407
P577
2010-04-14T00:00:00Z